Alan Rong

Alan Rong

Astellas Pharma Inc - Tokyo / Japan
Medical and Health Sciences / Biostatistics
AD Scientific Index ID: 4403927
アステラス製薬株式会社
person_outline Alan Rong's MOST POPULAR ARTICLES
1-) Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer New England Journal of Medicine 369 (11), 1023-1034, 2013
2-) Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with … Journal of clinical oncology 28 (31), 4706-4713, 2010
3-) Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for … Journal of Clinical Oncology 31 (15_suppl), 3511-3511, 2013
4-) Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer Cancer treatment reviews 41 (8), 653-659, 2015
5-) 14LBA Randomized phase 3 study of panitumumab with FOLFIRI vs FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC)M Peeters, T Price, Y Hotko, A Cervantes, M Ducreux, T André, E Chan, ...European Journal of Cancer Supplements 7 (3), 10, 2009692009